Abstract
Whilst multiple sclerosis (MS) can be conceptualized as a network disorder, brain network analyses are typically dependent on advanced MRI sequences not commonly acquired in clinical practice. Here, we used conventional MRI to assess cross-sectional and longitudinal modifications of structural disconnection and morphometric similarity networks in people with MS (pwMS), along with their relationship with clinical disability.
In this longitudinal monocentric study, 3T structural MRI scans of pwMS and healthy controls (HC) were retrospectively analysed. Physical and cognitive disabilities were assessed with the expanded disability status scale (EDSS) and the symbol digit modalities test (SDMT), respectively. Demyelinating lesions were automatically segmented on 3D-T1w and FLAIR images and, based on normative tractography data, the corresponding masks were used to compute pairwise structural disconnection between atlas-defined brain regions (100 cortical and 14 subcortical). Using the Morphometric Inverse Divergence (MIND) method, we built matrices of morphometric similarity between cortical regions based on FreeSurfer surface reconstruction. Using network-based statistics (NBS) and its prediction-based extension NBS-predict, we tested whether subject-level connectomes were associated with disease status, progression, clinical disability, and long-term confirmed disability progression (CDP), independently from global lesion burden and atrophy. The coupling between structural disconnection and morphometric similarity was assessed at different scales.
We studied 461 pwMS (age 37.2±10.6 years, F/M 324/137), corresponding to 1235 visits (mean follow-up time 1.9±2.0 years, range 0.1-13.3 years), and 55 HC (age 42.4±15.7 years; F/M 25/30). Long-term clinical follow-up was available for 285 pwMS (mean follow-up time 12.4±2.8 years), 127 of whom (44.6%) exhibited CDP. At baseline, structural disconnection in pwMS was mostly centered around the thalami and cortical sensory and association hubs, while morphometric similarity was extensively disrupted (pFWE<0.01). EDSS was related to fronto-thalamic disconnection (pFWE<0.01) and disrupted morphometric similarity around the left perisylvian cortex (pFWE 0.02), whilst SDMT was associated with cortico-subcortical disconnection in the left hemisphere (pFWE<0.01). Longitudinally, both structural disconnection and morphometric similarity disruption significantly progressed (pFWE 0.04 and pFWE<0.01), correlating with EDSS increase (rho 0.07, p 0.02 and rho 0.11, p<0.001), whilst baseline disconnection predicted long-term CDP with nearly 60% accuracy (p 0.03). On average, structural disconnection and morphometric similarity were positively associated at both the edge (rho 0.18, p<0.001) and node (rho 0.16, p<0.001) levels.
Structural disconnection and morphometric similarity networks, as assessed through conventional MRI, are sensitive to MS-related brain damage and its progression. They explain disease-related clinical disability and predict its long-term evolution independently from global lesion burden and atrophy, potentially adding to established MRI measures as network-based biomarkers of disease severity and progression.
Competing Interest Statement
M.P. discloses travel/meeting expenses from Novartis, Janssen, Roche and Merck; speaking honoraria from HEALTH&LIFE S.r.l., AIM Education S.r.l., Biogen, Novartis and FARECOMUNICAZIONE E20; honoraria for consulting services and advisory board participation from Biogen; research grants from Baroni Foundation and the Italian Ministry of University and Research (PRIN 2022LP5X2E). M.M. has received financial support by the MUR PNRR Extended Partnership (MNESYS no. PE00000006, and DHEAL-COM no. PNC-E3-2022-23683267); research grants from the ECTRIMS-MAGNIMS, the UK MS Society, and Merck; salary as Assistant Editor of Neurology; and honoraria from Abbvie, Biogen, BMS Celgene, Ipsen, Jansenn, Merck, Novartis, Roche, and Sanofi-Genzyme A.C. disclosed research grants from ECTRIMS-MAGNIMS and Almirall, travel/meeting expenses from Novartis, Janssen, Roche and Merck and speaking honoraria from Merk, BMS, Biogen, Novartis, Roche and Almirall. F.B.: Steering committee and iDMC member for Biogen, Merck, Roche, EISAI. Consultant for Roche, Biogen, Merck, IXICO, Jansen, Combinostics. Research agreements with Novartis, Merck, Biogen, GE, Roche. Co-founder and shareholder of Queen Square Analytics LTD. M.M.S. serves on the editorial board of Neurology and Frontiers in Neurology, receives research support from the Dutch MS Research Foundation, Eurostars-EUREKA, ARSEP, Amsterdam Neuroscience, MAGNIMS, and ZonMW and has served as a consultant for or received research support from Atara Biotherapeutics, Biogen, Celgene/Bristol Meyers Squibb, Genzyme, MedDay and Merck. A.T. has received speaker honoraria from Merck, Biomedia, Sereno Symposia International Foundation, Bayer and At the Limits and meeting expenses from Merck, Biogen Idec and Novartis He was the UK PI for two clinical trials sponsored by MEDDAY pharmaceutical company (MD1003 in optic neuropathy [MS-ON - NCT02220244] and progressive MS [MS-SPI2 - NCT02936037]). He has been supported by recent grants from the MRC (MR/S026088/1), NIHR BRC (541/CAP/OC/818837) and RoseTrees Trust (A1332 and PGL21/10079). He is an associate editor for Frontiers in Neurology - Neuro-ophthalmology section and on the editorial board for Neurology and Multiple Sclerosis Journal. S.C. has served on scientific advisory board for Amicus Therapeutics, has received speaker honoraria from Sanofi and research grants from Fondazione Italiana Sclerosi Multipla and Telethon. G.P. has received research grants from ECTRIMS (2022), MAGNIMS (2020), and ESNR (2021).
Funding Statement
This research received no specific grant from any funding agency in the public, commercial, or not‐for‐profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee Carlo Romano of the University of Naples Federico II gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes